Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Vir Biotechnology Inc.
Sponsor

Vir Biotechnology Inc.

United States 1800 Owens Street Suite 900, 94158-2388, United States

About the sponsor

Clinical research in chronic hepatitis B centers on investigational antiviral approaches aimed at controlling persistent infection and reducing viral activity. The sponsor’s work in this area includes studies of novel regimens designed to address long-standing HBV infection and related treatment outcomes.

  • Antiviral treatment for persistent HBV infection
  • Viral suppression and serologic response
  • Safety and tolerability of combination regimens

These trials reflect a focus on chronic viral liver disease and the development of therapies with potential to improve disease control in hepatology.

About Specializations

Vir Biotechnology Inc. runs clinical trials in conditions such as Hepatitis D, Hepatitis B, Chronic hepatitis B, among others.

All trials

Ongoing trials

Clinical trials registered by this sponsor – none is enrolling right now.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

6 clinical trials

Hepatitis D+1

Not recruiting

Study on the Effects of Tobevibart and Elebsiran Compared to Bulevirtide for Patients with Chronic Hepatitis D Virus Infection

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bulevirtide
  • Sponsor:Vir Biotechnology Inc.

Hepatitis D+1

Not recruiting

Study on Tobevibart and Elebsiran for Patients with Chronic Hepatitis D Virus Infection Not Responding to Bulevirtide Treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bulevirtide
  • Sponsor:Vir Biotechnology Inc.

Hepatitis D+1

Not recruiting

Study on Tobevibart and Elebsiran for Patients with Chronic Hepatitis D Virus Infection

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Elebsiran
  • Sponsor:Vir Biotechnology Inc.

Hepatitis D+1

Not recruiting

Study on the Effects of VIR-2218 and VIR-3434 for Patients with Chronic Hepatitis D Infection

InvestigationalNo placebo
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Elebsiran
  • Sponsor:Vir Biotechnology Inc.

Chronic hepatitis B

Not recruiting

Study on the Safety and Effectiveness of VIR-2218, VIR-3434, and Peginterferon Alfa-2a for Patients with Chronic Hepatitis B

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Elebsiran
  • Sponsor:Vir Biotechnology Inc.

Chronic hepatitis B

Not recruiting

Study on the Effects of Peginterferon Alfa-2a, Tobevibart, and Elebsiran in Patients with Chronic Hepatitis B Infection

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Elebsiran
  • Sponsor:Vir Biotechnology Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.